Eligibility for vericiguat in a real‐world, contemporary heart failure population

Abstract Aims Vericiguat is a soluble guanylate cyclase stimulator and improves survival in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and an increased risk of decompensation. As real‐world data on how many patients could be eligible for vericiguat therapy derive from ou...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Giuseppe Vergaro, Alberto Aimo, Francesco Gentile, Giulia Elena Mandoli, Marta Focardi, Vincenzo Castiglione, Alberto Giannoni, Giorgia Panichella, Alessandra Fornaro, Erberto Carluccio, Riccardo Liga, Mattia Salatin, Claudio Passino, Massimo F. Piepoli, Matteo Cameli, Francesco Cappelli, Carlo Di Mario, Michele Emdin
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Oxford University Press 2024-12-01
סדרה:	ESC Heart Failure
נושאים:	Vericiguat Heart failure Therapy Guidelines Population
גישה מקוונת:	https://doi.org/10.1002/ehf2.14767
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!